A Phase 3 interventional study of ranibizumab in Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 26th largest by enrollment, is one of 5 that started in 2011, is one of 13 in phase 3, and was the 17th registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 14 · Phase 4 13
First in 2006; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is close to the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 56 across the 47 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
20 studies in Retinal Vein Occlusion by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 14 (70%) have results posted.
Among the 20 studies in Retinal Vein Occlusion by Novartis, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 3, and was the 3rd registered.
Novartis’s Retinal Vein Occlusion studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 20 in Retinal Vein Occlusion:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein occlusion (BRVO or CRVO) to support the applicability of the phase III study results of BRAVO and CRUISE in this indication, in the Japanese ethnic patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ranibizumab
Measure: Efficacy of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab as assessed by the mean average change in best-corrected visual acuity (BCVA) from Month 1 through Month 3 compared to baseline
Time frame: 3 months
Measure: Efficacy of monthly ranibizumab injections as assessed by the mean BCVA change from baseline over time to Month 3, by visit
Time frame: 3 months
Measure: Efficacy of monthly ranibizumab injections as assessed by the mean change in central subfield thickness (CSFT) of the retina from baseline over time to Month 3
Time frame: 3 months
Measure: Efficacy of monthly ranibizumab injections as assessed by the proportion of patients achieving BCVA improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters from baseline to Month 3
Time frame: 3 months
Measure: Efficacy of monthly ranibizumab injections as assessed by the proportion of patients with a BCVA loss of <15 letters from baseline to Month 3
Time frame: 3 months
Measure: Safety of monthly ranibizumab injections as assessed by the type, frequency and severity of adverse events
Time frame: 3 months
The record gives a start of Jun 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab